198 related articles for article (PubMed ID: 16740758)
1. Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer.
Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F; Smith MR
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3361-7. PubMed ID: 16740758
[TBL] [Abstract][Full Text] [Related]
2. Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancer.
Smith MR; Cook RJ; Coleman R; Brown J; Lipton A; Major P; Hei YJ; Saad F
Urology; 2007 Aug; 70(2):315-9. PubMed ID: 17826496
[TBL] [Abstract][Full Text] [Related]
3. Bone-related Parameters are the Main Prognostic Factors for Overall Survival in Men with Bone Metastases from Castration-resistant Prostate Cancer.
Fizazi K; Massard C; Smith M; Rader M; Brown J; Milecki P; Shore N; Oudard S; Karsh L; Carducci M; Damião R; Wang H; Ying W; Goessl C
Eur Urol; 2015 Jul; 68(1):42-50. PubMed ID: 25449207
[TBL] [Abstract][Full Text] [Related]
4. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors.
Brown JE; Cook RJ; Major P; Lipton A; Saad F; Smith M; Lee KA; Zheng M; Hei YJ; Coleman RE
J Natl Cancer Inst; 2005 Jan; 97(1):59-69. PubMed ID: 15632381
[TBL] [Abstract][Full Text] [Related]
5. Significance of baseline bone markers on disease progression and survival in hormone-sensitive prostate cancer with bone metastasis.
Nozawa M; Hara I; Matsuyama H; Iki M; Nagao K; Nishioka T; Komura T; Esa A; Uejima S; Imanishi M; Uekado Y; Ogawa T; Kajikawa H; Uemura H
World J Urol; 2015 Sep; 33(9):1263-8. PubMed ID: 25354720
[TBL] [Abstract][Full Text] [Related]
6. Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer.
Rajpar S; Massard C; Laplanche A; Tournay E; Gross-Goupil M; Loriot Y; Di Palma M; Bossi A; Escudier B; Chauchereau A; Fizazi K
Ann Oncol; 2010 Sep; 21(9):1864-1869. PubMed ID: 20181574
[TBL] [Abstract][Full Text] [Related]
7. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
Som A; Tu SM; Liu J; Wang X; Qiao W; Logothetis C; Corn PG
Br J Cancer; 2012 Oct; 107(9):1547-53. PubMed ID: 23033003
[TBL] [Abstract][Full Text] [Related]
8. Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity.
Hirsh V; Major PP; Lipton A; Cook RJ; Langer CJ; Smith MR; Brown JE; Coleman RE
J Thorac Oncol; 2008 Mar; 3(3):228-36. PubMed ID: 18317064
[TBL] [Abstract][Full Text] [Related]
9. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer.
Smith MR; Kabbinavar F; Saad F; Hussain A; Gittelman MC; Bilhartz DL; Wynne C; Murray R; Zinner NR; Schulman C; Linnartz R; Zheng M; Goessl C; Hei YJ; Small EJ; Cook R; Higano CS
J Clin Oncol; 2005 May; 23(13):2918-25. PubMed ID: 15860850
[TBL] [Abstract][Full Text] [Related]
10. Skeletal-related events and clinical outcomes in patients with bone metastases and normal levels of osteolysis: exploratory analyses.
Lipton A; Cook R; Brown J; Body JJ; Smith M; Coleman R
Clin Oncol (R Coll Radiol); 2013 Apr; 25(4):217-26. PubMed ID: 23219232
[TBL] [Abstract][Full Text] [Related]
11. Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade.
Kamiya N; Suzuki H; Endo T; Takano M; Yano M; Naoi M; Nishimi D; Kawamura K; Imamoto T; Ichikawa T
Int J Urol; 2012 Feb; 19(2):169-73. PubMed ID: 22126137
[TBL] [Abstract][Full Text] [Related]
12. Analysis of biochemical bone markers as prognostic factors for survival in patients with hormone-resistant prostate cancer and bone metastases.
Petrioli R; Rossi S; Caniggia M; Pozzessere D; Messinese S; Sabatino M; Marsili S; Correale P; Salvestrini F; Manganelli A; Francini G
Urology; 2004 Feb; 63(2):321-6. PubMed ID: 14972482
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model.
Gravis G; Boher JM; Fizazi K; Joly F; Priou F; Marino P; Latorzeff I; Delva R; Krakowski I; Laguerre B; Walz J; Rolland F; Théodore C; Deplanque G; Ferrero JM; Pouessel D; Mourey L; Beuzeboc P; Zanetta S; Habibian M; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Labourey JL; Machiels JP; El Kouri C; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Soulie M; Oudard S
Eur Urol; 2015 Aug; 68(2):196-204. PubMed ID: 25277272
[TBL] [Abstract][Full Text] [Related]
14. Prospective Evaluation of Zoledronic Acid in the Treatment of Bone Metastases from Differentiated Thyroid Carcinoma.
Orita Y; Sugitani I; Takao S; Toda K; Manabe J; Miyata S
Ann Surg Oncol; 2015 Nov; 22(12):4008-13. PubMed ID: 25762482
[TBL] [Abstract][Full Text] [Related]
15. Failure to suppress markers of bone turnover on first-line hormone therapy for metastatic prostate cancer is associated with shorter time to skeletal-related event.
Hahn NM; Yiannoutsos CT; Kirkpatrick K; Sharma J; Sweeney CJ
Clin Genitourin Cancer; 2014 Feb; 12(1):33-40.e4. PubMed ID: 24126237
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
[TBL] [Abstract][Full Text] [Related]
17. Serum lactate dehydrogenase is prognostic for survival in patients with bone metastases from breast cancer: a retrospective analysis in bisphosphonate-treated patients.
Brown JE; Cook RJ; Lipton A; Coleman RE
Clin Cancer Res; 2012 Nov; 18(22):6348-55. PubMed ID: 22952345
[TBL] [Abstract][Full Text] [Related]
18. Impact of race on survival in men with metastatic hormone-refractory prostate cancer.
Halabi S; Small EJ; Vogelzang NJ; Barrier RC; George SL; Gilligan TD
Urology; 2004 Aug; 64(2):212-7. PubMed ID: 15302462
[TBL] [Abstract][Full Text] [Related]
19. Re: A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma.
Berruti A; Tucci M; Terrone C; Scarpa RM; Angeli A; Dogliotti L
J Natl Cancer Inst; 2003 Feb; 95(4):332-3; author reply 333-4. PubMed ID: 12591993
[No Abstract] [Full Text] [Related]
20. Disease and host characteristics as predictors of time to first bone metastasis and death in men with progressive castration-resistant nonmetastatic prostate cancer.
Smith MR; Cook R; Lee KA; Nelson JB
Cancer; 2011 May; 117(10):2077-85. PubMed ID: 21523719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
